secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001683168-24-001993
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma reports 2023 sales $24.1M, loss per share improves to -$0.19
-------------------------------------------------------------------------------

- Sales grew to $24,092,787 in 2023 from $4,345,603 in 2022; average quarter-over-quarter growth of 14%.
- Net loss narrowed to $4,506,044 from $26,744,440; loss per share improved to -$0.19 from -$1.76.
- Gross profit rose to $8,339,171 from $1,696,575; G&A expenses reduced to $13.1M from $28.7M.
- Completed $5M private placement; repurchased 513,723 shares for $541,143.
- Two proprietary drugs advanced to animal testing; IND-enabling studies for Adva-27a halted in November 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824001993/0001683168-24-001993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824001993/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-001993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer